{"id":65696,"date":"2026-05-19T23:00:17","date_gmt":"2026-05-19T15:00:17","guid":{"rendered":"https:\/\/flcube.com\/?p=65696"},"modified":"2026-05-19T23:00:18","modified_gmt":"2026-05-19T15:00:18","slug":"bayers-hyrnuo-receives-fda-priority-review-for-first-line-her2-mutated-nsclc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65696","title":{"rendered":"Bayer&#8217;s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment"},"content":{"rendered":"\n<p><strong>Bayer AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>Priority Review<\/strong> status to <strong>HYRNUO (sevabertinib)<\/strong> for the <strong>first-line treatment of adult patients<\/strong> with <strong>locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/strong> whose tumors harbor <strong>HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations<\/strong> and who have <strong>received no prior therapy<\/strong>. This regulatory milestone follows HYRNUO&#8217;s <strong>accelerated approval in November 2025<\/strong> for previously treated patients, potentially expanding its indication to the frontline setting.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-timeline-amp-indication-evolution\">Regulatory Timeline &amp; Indication Evolution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Previous Approval<\/th><th>New Priority Review Application<\/th><\/tr><\/thead><tbody><tr><td><strong>November 2025<\/strong>: Accelerated approval for <strong>previously treated patients<\/strong> with HER2 TKD activating mutations<\/td><td><strong>May 2026<\/strong>: Priority Review for <strong>first-line treatment<\/strong> in treatment-na\u00efve patients with HER2 TKD activating mutations<\/td><\/tr><tr><td><strong>Patient Population<\/strong>: Post-systemic therapy<\/td><td><strong>Patient Population<\/strong>: No prior therapy<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong>: Ongoing<\/td><td><strong>Potential Approval<\/strong>: Q3-Q4 2026 (6-month PDUFA timeline)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>HYRNUO (sevabertinib)<\/strong> represents a <strong>next-generation tyrosine kinase inhibitor<\/strong> with selective targeting capabilities:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: <strong>Oral, reversible, small molecule TKI<\/strong> inhibiting <strong>mutated human HER2<\/strong>, including <strong>HER2 exon 20 insertions<\/strong> and <strong>HER2 point mutations<\/strong><\/li>\n\n\n\n<li><strong>Selectivity Profile<\/strong>: Demonstrates <strong>preference for mutated vs wild-type EGFR<\/strong>, potentially reducing off-target toxicity<\/li>\n\n\n\n<li><strong>Additional Targets<\/strong>: Also inhibits <strong>epidermal growth factor receptors (EGFR)<\/strong>, providing broad activity against HER family mutations<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Oral dosing enables convenient outpatient treatment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-supporting-first-line-application\">Clinical Evidence Supporting First-Line Application<\/h2>\n\n\n\n<p>The regulatory submission is based on <strong>preliminary clinical evidence<\/strong> from <strong>Cohort F<\/strong> of the ongoing <strong>Phase 1\/2 SOHO-01 Study (NCT05099172)<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population<\/strong>: Treatment-na\u00efve patients with <strong>locally advanced or metastatic HER2-mutated NSCLC<\/strong><\/li>\n\n\n\n<li><strong>Study Design<\/strong>: Single-arm cohort evaluating <strong>efficacy and safety<\/strong> of HYRNUO monotherapy<\/li>\n\n\n\n<li><strong>Primary Endpoints<\/strong>: Objective response rate (ORR), duration of response (DOR), and safety profile<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Priority Review designation reflects <strong>substantial improvement<\/strong> over available therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER2-Mutated NSCLC Burden<\/strong>: Approximately <strong>4,000-6,000 new cases annually<\/strong> in the U.S., representing significant unmet need<\/li>\n\n\n\n<li><strong>Current Standard<\/strong>: Limited effective options in first-line setting, with chemotherapy providing modest benefit<\/li>\n\n\n\n<li><strong>Competitive Differentiation<\/strong>: HYRNUO would be among the first <strong>HER2-specific TKIs<\/strong> approved for first-line use in this molecularly defined population<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong>: Analysts project peak annual sales of <strong>$800 million to $1.2 billion<\/strong> with first-line indication expansion<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-for-bayer-oncology\">Strategic Implications for Bayer Oncology<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion<\/strong>: Strengthens Bayer&#8217;s position in <strong>precision oncology<\/strong> and <strong>molecularly targeted therapies<\/strong><\/li>\n\n\n\n<li><strong>HER2 Franchise Development<\/strong>: Establishes foundation for potential expansion into other <strong>HER2-mutated solid tumors<\/strong><\/li>\n\n\n\n<li><strong>Revenue Growth<\/strong>: First-line indication could <strong>double or triple<\/strong> current market opportunity compared to second-line only<\/li>\n\n\n\n<li><strong>Global Strategy<\/strong>: U.S. approval likely to support <strong>simultaneous filings<\/strong> with EMA and other major regulatory agencies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-priority-review-significance\">Priority Review Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Timeline<\/strong>: <strong>6-month review period<\/strong> (vs standard 10 months) indicates FDA recognition of <strong>significant therapeutic advance<\/strong><\/li>\n\n\n\n<li><strong>Clinical Need<\/strong>: Addresses <strong>serious condition<\/strong> with <strong>lack of adequate existing treatments<\/strong> in first-line setting<\/li>\n\n\n\n<li><strong>Regulatory Momentum<\/strong>: Builds on successful <strong>accelerated approval pathway<\/strong> established in November 2025<\/li>\n\n\n\n<li><strong>Market Exclusivity<\/strong>: Potential for <strong>additional exclusivity periods<\/strong> beyond standard patent protection<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-amp-tolerability-considerations\">Safety &amp; Tolerability Considerations<\/h2>\n\n\n\n<p>While detailed safety data from Cohort F was not disclosed, HYRNUO&#8217;s established profile suggests:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manageable Toxicity<\/strong>: Selective targeting of mutated EGFR may reduce <strong>wild-type EGFR-related adverse events<\/strong> (rash, diarrhea)<\/li>\n\n\n\n<li><strong>Oral Convenience<\/strong>: Outpatient administration reduces <strong>healthcare resource utilization<\/strong><\/li>\n\n\n\n<li><strong>Quality of Life<\/strong>: Targeted therapy approach typically provides <strong>better tolerability<\/strong> than chemotherapy regimens<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-commercial-readiness-amp-market-access\">Commercial Readiness &amp; Market Access<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diagnostic Partnership<\/strong>: FDA-approved companion diagnostic ensures <strong>appropriate patient selection<\/strong><\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: Premium pricing expected given <strong>targeted nature<\/strong> and <strong>clinical benefit<\/strong> in difficult-to-treat population<\/li>\n\n\n\n<li><strong>Reimbursement Pathway<\/strong>: Established precedent for <strong>HER2-targeted therapies<\/strong> supports favorable coverage decisions<\/li>\n\n\n\n<li><strong>Physician Adoption<\/strong>: Clear molecular selection criteria facilitate <strong>rapid integration<\/strong> into clinical practice<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations for HYRNUO. Actual results may differ due to risks including final FDA review outcomes, competitive dynamics, market adoption rates, and clinical trial final results.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65697,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[269,967,80],"class_list":["post-65696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bayer","tag-etr-bayn","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer&#039;s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to HYRNUO (sevabertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and who have received no prior therapy. This regulatory milestone follows HYRNUO&#039;s accelerated approval in November 2025 for previously treated patients, potentially expanding its indication to the frontline setting.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65696\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer&#039;s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to HYRNUO (sevabertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and who have received no prior therapy. This regulatory milestone follows HYRNUO&#039;s accelerated approval in November 2025 for previously treated patients, potentially expanding its indication to the frontline setting.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65696\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T15:00:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T15:00:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1907.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer&#8217;s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment\",\"datePublished\":\"2026-05-19T15:00:17+00:00\",\"dateModified\":\"2026-05-19T15:00:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696\"},\"wordCount\":631,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1907.webp\",\"keywords\":[\"Bayer\",\"ETR: BAYN\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65696#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65696\",\"name\":\"Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1907.webp\",\"datePublished\":\"2026-05-19T15:00:17+00:00\",\"dateModified\":\"2026-05-19T15:00:18+00:00\",\"description\":\"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to HYRNUO (sevabertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and who have received no prior therapy. This regulatory milestone follows HYRNUO's accelerated approval in November 2025 for previously treated patients, potentially expanding its indication to the frontline setting.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65696\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1907.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1907.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65696#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer&#8217;s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to HYRNUO (sevabertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and who have received no prior therapy. This regulatory milestone follows HYRNUO's accelerated approval in November 2025 for previously treated patients, potentially expanding its indication to the frontline setting.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65696","og_locale":"en_US","og_type":"article","og_title":"Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment","og_description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to HYRNUO (sevabertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and who have received no prior therapy. This regulatory milestone follows HYRNUO's accelerated approval in November 2025 for previously treated patients, potentially expanding its indication to the frontline setting.","og_url":"https:\/\/flcube.com\/?p=65696","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T15:00:17+00:00","article_modified_time":"2026-05-19T15:00:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1907.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65696#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65696"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer&#8217;s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment","datePublished":"2026-05-19T15:00:17+00:00","dateModified":"2026-05-19T15:00:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65696"},"wordCount":631,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65696#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1907.webp","keywords":["Bayer","ETR: BAYN","Priority reviews"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65696#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65696","url":"https:\/\/flcube.com\/?p=65696","name":"Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65696#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65696#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1907.webp","datePublished":"2026-05-19T15:00:17+00:00","dateModified":"2026-05-19T15:00:18+00:00","description":"Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to HYRNUO (sevabertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and who have received no prior therapy. This regulatory milestone follows HYRNUO's accelerated approval in November 2025 for previously treated patients, potentially expanding its indication to the frontline setting.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65696#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65696"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65696#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1907.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1907.webp","width":1080,"height":608,"caption":"Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65696#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer&#8217;s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1907.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65696"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65696\/revisions"}],"predecessor-version":[{"id":65698,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65696\/revisions\/65698"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65697"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}